All In MedTech

FDA Clearance Tracker · P150005-S074

INTELLANAV STABLEPOINT™ Ablation Catheter & Force Sensing System on the RHYTHMIA HDX™ Mapping System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 26, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 26, 2024

Approved

Time to decision

388 days

Received Feb 3, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150005-S074
Device name
INTELLANAV STABLEPOINT™ Ablation Catheter & Force Sensing System on the RHYTHMIA HDX™ Mapping System
Applicant location
St Paul, MN
Received
Feb 3, 2023
Decided
Feb 26, 2024
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P150005

Device type

Device class
Class III

Every decision under product code OAE

FDA's approval statement

As written in FDA's record.

Approval for INTELLANAV STABLEPOINT™ Ablation Catheter & Force Sensing System on the RHYTHMIA HDX™ Mapping SystemThe INTELLANAV STABLEPOINT Catheter, when used with a compatible Radiofrequency Controller and IrrigationPump, is indicated for:• Cardiac electrophysiological mapping• Delivering diagnostic pacing stimuli• RF ablation of sustained or recurrent typical atrial flutter in patients age 18 years or older• Treatment of drug refractory, recurrent, symptomatic, Paroxysmal Atrial Fibrillation (PAF) in patients age 18 years or older, when used with a compatible mapping system

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.